A/S Genmab Buys 561,042 Shares of Merus (NASDAQ:MRUS) Stock

Posted by ABMN Staff on Dec 31st, 2025

Merus N.V. (NASDAQ:MRUS – Get Free Report) major shareholder A/S Genmab purchased 561,042 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was bought at an average price of $97.00 per share, for a total transaction of $54,421,074.00. Following the transaction, the insider directly owned 72,589,817 shares in the company, valued at $7,041,212,249. This trade represents a 0.78% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

A/S Genmab also recently made the following trade(s):

On Monday, December 29th, A/S Genmab purchased 1,052,806 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, with a total value of $102,122,182.00.
On Friday, December 26th, A/S Genmab acquired 2,978 shares of Merus stock. The stock was purchased at an average price of $97.00 per share, for a total transaction of $288,866.00.
On Friday, December 26th, A/S Genmab acquired 142,610 shares of Merus stock. The shares were purchased at an average price of $97.00 per share, with a total value of $13,833,170.00.
On Wednesday, December 24th, A/S Genmab bought 96,082 shares of Merus stock. The stock was purchased at an average price of $97.00 per share, with a total value of $9,319,954.00.
On Monday, December 22nd, A/S Genmab bought 15,710 shares of Merus stock. The stock was purchased at an average cost of $97.00 per share, for a total transaction of $1,523,870.00.
On Friday, December 19th, A/S Genmab purchased 66,264 shares of Merus stock. The shares were purchased at an average price of $97.00 per share, for a total transaction of $6,427,608.00.
On Thursday, December 18th, A/S Genmab acquired 212,177 shares of Merus stock. The stock was purchased at an average price of $97.00 per share, with a total value of $20,581,169.00.
On Wednesday, December 17th, A/S Genmab acquired 150,795 shares of Merus stock. The stock was acquired at an average cost of $97.00 per share, for a total transaction of $14,627,115.00.
On Tuesday, December 16th, A/S Genmab bought 120,752 shares of Merus stock. The shares were acquired at an average price of $97.00 per share, for a total transaction of $11,712,944.00.

Merus Price Performance

MRUS opened at $90.00 on Wednesday. Merus N.V. has a 12 month low of $33.19 and a 12 month high of $97.14. The stock has a market capitalization of $6.83 billion, a P/E ratio of -16.98 and a beta of 1.06. The business has a 50 day simple moving average of $95.69 and a 200-day simple moving average of $78.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in Merus by 9.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,924 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 250 shares in the last quarter. US Bancorp DE raised its stake in shares of Merus by 7.1% during the third quarter. US Bancorp DE now owns 3,993 shares of the biotechnology company’s stock valued at $376,000 after purchasing an additional 266 shares during the period. Avanza Fonder AB lifted its position in shares of Merus by 14.1% during the second quarter. Avanza Fonder AB now owns 3,136 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 387 shares in the last quarter. Knights of Columbus Asset Advisors LLC boosted its stake in shares of Merus by 3.4% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 13,614 shares of the biotechnology company’s stock valued at $1,282,000 after purchasing an additional 442 shares during the period. Finally, Quarry LP purchased a new position in shares of Merus during the 3rd quarter valued at approximately $42,000. 96.14% of the stock is owned by hedge funds and other institutional investors.

More Merus News

Here are the key news stories impacting Merus this week:

Positive Sentiment: A/S Genmab (a major shareholder) has accumulated large blocks of Merus stock across Dec. 16–29, including a reported 1,052,806‑share purchase on Dec. 29 at ~$97 per share — increasing its stake and signaling strong insider/acquirer conviction. This sizeable, repeated buying can be interpreted as bullish support under the shares. SEC Ownership Filing
Positive Sentiment: Large institutional investors have also added positions in recent quarters (e.g., Paradigm Biocapital, Magnetar, Ameriprise), indicating continued institutional interest that can support the longer‑term valuation case. MarketBeat Institutional Ownership
Neutral Sentiment: Trading of MRUS was temporarily halted with a “news pending” notice — a procedural event that typically precedes material announcements and can cause short‑term volume/volatility without indicating direction. (Reported earlier today.)
Neutral Sentiment: Unusually large options activity has been reported in MRUS recently; such flows often reflect speculative positioning or hedging and tend to increase intraday volatility but are ambiguous for price direction. Options Flow Report
Negative Sentiment: Reports indicate Merus has completed a Genmab acquisition and will delist from Nasdaq — a material corporate action that can reduce public float/liquidity and prompt re‑pricing or forced selling by some investors; that development is a likely contributor to the pullback in the stock. TipRanks: Acquisition/Delisting

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MRUS. Guggenheim reaffirmed a “neutral” rating and set a $97.00 price target (down from $109.00) on shares of Merus in a research note on Tuesday, September 30th. BMO Capital Markets restated a “market perform” rating and set a $97.00 target price on shares of Merus in a research report on Friday, October 31st. Canaccord Genuity Group downgraded shares of Merus from a “buy” rating to a “hold” rating and lifted their price target for the company from $67.00 to $97.00 in a research report on Monday, September 29th. Needham & Company LLC lowered Merus from a “buy” rating to a “hold” rating and set a $96.00 price target on the stock. in a research note on Monday, September 29th. Finally, Barclays restated an “equal weight” rating and issued a $97.00 price target (down previously from $112.00) on shares of Merus in a report on Tuesday, September 30th. Three research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $93.56.

Read Our Latest Analysis on MRUS

Merus Company Profile

(Get Free Report)

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.